Wei Zhang1, Hui Liu1, Junjie Jiang1, Yunyun Yang2, Wenjie Wang3, Zhengyan Jia4. 1. Department of Thyroid and Breast I, Cangzhou Central Hospital Cangzhou, China. 2. Outpatient Comprehensive Treatment, Cangzhou Central Hospital Cangzhou, China. 3. Department of General Surgery, Botou Hospital Botou, Hebei, China. 4. Department of General Surgery, Qingxian People's Hospital Qingxian, Hebei, China.
Abstract
BACKGROUND: Triple-negative breast cancer (TNBC) has rapid development and a worse prognosis, without special treatment. It is necessary to explore targeted treatment. OBJECTIVE: To explore the significance of CD147 and matrix metalloproteinase-9 (MMP-9) in TNBC and their influence on prognosis. METHODS: 81 TNBC patients admitted to our hospital and 86 healthy individuals undergoing physical examination from August 2014 to August 2016 were included. The concentrations of serum CD147 and MMP-9, their diagnostic value, and their relationship with clinicopathologic features were analyzed. A 3-year follow-up visit was conducted to assess the prognostic effect of CD147. Its effect on the biologic behavior of breast cancer cells was also determined. RESULTS: Higher serum CD147 and MMP-9 levels were found in TNBC patients than healthy individuals (P<0.05). CD147 and MMP-9 were closely related to the pathologic stage, metastasis, and differentiation of the tumors (P<0.05). A positive correlation between CD147 and MMP-9 was detected before chemotherapy (n=127, r=0.609, P<0.01), with similar expression rates of CD147 (76.9%) and MMP-9 (80.67%) (P>0.05). The 2 markers were independent risk factors for poor prognosis in TNBC (PCD147=0.023; PMMP-9=0.015), and increased CD147/MMP-9 expression was significantly related to treatment failure. After chemotherapy, the expression of CD147 in TNBC patients decreased, and higher expression predicted death (P<0.05). The sensitivity and specificity of CD147 for death in 3-year follow-up were 76.92% and 88.89%, and the expression of CD147 in breast cancer cells was increased (P<0.001). Interfering with CD147 can decrease the proliferation and invasion of breast cancer cells and increase apoptotic rate (P<0.05). CONCLUSION: CD147 can promote the proliferation and invasion of breast cancer cells, which underlines its value in the diagnosis and treatment of TNBC. AJTR
BACKGROUND: Triple-negative breast cancer (TNBC) has rapid development and a worse prognosis, without special treatment. It is necessary to explore targeted treatment. OBJECTIVE: To explore the significance of CD147 and matrix metalloproteinase-9 (MMP-9) in TNBC and their influence on prognosis. METHODS: 81 TNBC patients admitted to our hospital and 86 healthy individuals undergoing physical examination from August 2014 to August 2016 were included. The concentrations of serum CD147 and MMP-9, their diagnostic value, and their relationship with clinicopathologic features were analyzed. A 3-year follow-up visit was conducted to assess the prognostic effect of CD147. Its effect on the biologic behavior of breast cancer cells was also determined. RESULTS: Higher serum CD147 and MMP-9 levels were found in TNBC patients than healthy individuals (P<0.05). CD147 and MMP-9 were closely related to the pathologic stage, metastasis, and differentiation of the tumors (P<0.05). A positive correlation between CD147 and MMP-9 was detected before chemotherapy (n=127, r=0.609, P<0.01), with similar expression rates of CD147 (76.9%) and MMP-9 (80.67%) (P>0.05). The 2 markers were independent risk factors for poor prognosis in TNBC (PCD147=0.023; PMMP-9=0.015), and increased CD147/MMP-9 expression was significantly related to treatment failure. After chemotherapy, the expression of CD147 in TNBC patients decreased, and higher expression predicted death (P<0.05). The sensitivity and specificity of CD147 for death in 3-year follow-up were 76.92% and 88.89%, and the expression of CD147 in breast cancer cells was increased (P<0.001). Interfering with CD147 can decrease the proliferation and invasion of breast cancer cells and increase apoptotic rate (P<0.05). CONCLUSION: CD147 can promote the proliferation and invasion of breast cancer cells, which underlines its value in the diagnosis and treatment of TNBC. AJTR
Authors: Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens Journal: N Engl J Med Date: 2018-10-20 Impact factor: 91.245
Authors: Joy M McDaniel; Katherine E Varley; Jason Gertz; Daniel S Savic; Brian S Roberts; Sarah K Bailey; Lalita A Shevde; Ryne C Ramaker; Brittany N Lasseigne; Marie K Kirby; Kimberly M Newberry; E Christopher Partridge; Angela L Jones; Braden Boone; Shawn E Levy; Patsy G Oliver; Katherine C Sexton; William E Grizzle; Andres Forero; Donald J Buchsbaum; Sara J Cooper; Richard M Myers Journal: Oncotarget Date: 2017-01-31
Authors: Hermela Shimelis; Holly LaDuca; Chunling Hu; Steven N Hart; Jie Na; Abigail Thomas; Margaret Akinhanmi; Raymond M Moore; Hiltrud Brauch; Angela Cox; Diana M Eccles; Amanda Ewart-Toland; Peter A Fasching; Florentia Fostira; Judy Garber; Andrew K Godwin; Irene Konstantopoulou; Heli Nevanlinna; Priyanka Sharma; Drakoulis Yannoukakos; Song Yao; Bing-Jian Feng; Brigette Tippin Davis; Jenna Lilyquist; Tina Pesaran; David E Goldgar; Eric C Polley; Jill S Dolinsky; Fergus J Couch Journal: J Natl Cancer Inst Date: 2018-08-01 Impact factor: 13.506